{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:43:50Z","timestamp":1782247430836,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7232254"],"award-info":[{"award-number":["7232254"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117687","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:33:45Z","timestamp":1746070425000},"page":"117687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design, synthesis, anticancer activity evaluation and molecular dynamics study of pyrazine N-oxide-based SHP2 allosteric inhibitors"],"prefix":"10.1016","volume":"293","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1642-7773","authenticated-orcid":false,"given":"Zhongjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangbao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117687_bib1","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2006-07-028829","article-title":"PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase","volume":"109","author":"Chan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117687_bib2","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1016\/j.apsb.2021.03.037","article-title":"Strategies to overcome drug resistance using SHP2 inhibitors","volume":"11","author":"Liu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117687_bib3","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1021\/acs.jmedchem.1c02008","article-title":"Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy","volume":"65","author":"Song","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib4","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.117687_bib5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/0008-5472.CAN-14-1215","article-title":"PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117687_bib6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.apsb.2018.08.009","article-title":"SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade","volume":"9","author":"Zhao","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117687_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2025.117687_bib8","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.1158\/0008-5472.CAN-04-1923","article-title":"Activating mutations of the noonan syndrome-associated SHP2\/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia","volume":"64","author":"Bentires-Alj","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117687_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.apsb.2020.07.010","article-title":"Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies","volume":"11","author":"Song","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117687_bib10","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2003-09-3287","article-title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis","volume":"103","author":"Loh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117687_bib11","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1038\/s41467-021-26697-8","article-title":"Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117687_bib12","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nm.2645","article-title":"Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop","volume":"18","author":"Aceto","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.117687_bib13","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1016\/j.apsb.2024.03.028","article-title":"Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor","volume":"14","author":"Tang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.117687_bib14","doi-asserted-by":"crossref","first-page":"11368","DOI":"10.1021\/acs.jmedchem.0c00249","article-title":"Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application","volume":"63","author":"Yuan","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115305","article-title":"Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-Driven cancer treatment","volume":"253","author":"Luo","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib16","doi-asserted-by":"crossref","first-page":"13646","DOI":"10.1021\/acs.jmedchem.3c00992","article-title":"Identification of a novel, potent, and orally bioavailable guanidine-based SHP2 allosteric inhibitor from virtual screening and rational structural optimization for the treatment of KRAS mutant cancers","volume":"66","author":"Hou","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116830","article-title":"Discovery of novel substituted pyridine carboxamide derivatives as potent allosteric SHP2 inhibitors","volume":"279","author":"Lv","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117687_bib19","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/med.21890","article-title":"Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery","volume":"42","author":"Song","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.117687_bib20","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/2159-8290.CD-23-0383","article-title":"SHP2: a pleiotropic target at the interface of cancer and its microenvironment","volume":"13","author":"Sodir","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.117687_bib21","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1084\/jem.20110450","article-title":"Non-lineage\/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells","volume":"208","author":"Xu","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2025.117687_bib22","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1124\/mol.106.025536","article-title":"Discovery of a novel shp2 protein tyrosine phosphatase inhibitor","volume":"70","author":"Chen","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117687_bib23","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1073\/pnas.0710468105","article-title":"Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking","volume":"105","author":"Hellmuth","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.117687_bib24","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1021\/jm901645u","article-title":"Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)","volume":"53","author":"Zhang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nature18621","article-title":"Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases","volume":"535","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117687_bib26","doi-asserted-by":"crossref","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","article-title":"Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer","volume":"63","author":"LaMarche","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib27","doi-asserted-by":"crossref","first-page":"13534","DOI":"10.1021\/acs.jmedchem.4c00360","article-title":"Discovery of JAB-3312, a potent SHP2 allosteric inhibitor for cancer treatment","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib28","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.1021\/acs.jmedchem.3c00483","article-title":"Identification of GDC-1971 (RLY-1971), a SHP2 inhibitor designed for the treatment of solid tumors","volume":"66","author":"Taylor","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib29","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1158\/0008-5472.CAN-20-1634","article-title":"Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward osimertinib","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117687_bib30","doi-asserted-by":"crossref","first-page":"13483","DOI":"10.1021\/acs.jmedchem.2c00969","article-title":"Recent scaffold hopping applications in central nervous system drug discovery","volume":"65","author":"Callis","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib31","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1021\/acs.jmedchem.4c00254","article-title":"Medicinal chemistry of drugs with N-Oxide functionalities","volume":"67","author":"Kobus","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib32","unstructured":"Amino acid sequence similarity and identity calculated by BLAST. https:\/\/blast.ncbi.nlm.nih.gov\/Blast.cgi."},{"key":"10.1016\/j.ejmech.2025.117687_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117036","article-title":"Discovery of novel phenyl urea SHP2 inhibitors with anti-colon cancer and potential immunomodulatory effects","volume":"281","author":"Wang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib34","article-title":"Optimization of SHP2 allosteric inhibitors with novel tail heterocycles and their potential as antitumor therapeutics","volume":"282","author":"Yu","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib35","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1074\/jbc.270.7.2897","article-title":"Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains","volume":"270","author":"Pluskey","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib36","doi-asserted-by":"crossref","first-page":"13305","DOI":"10.1021\/acs.jmedchem.4c01217","article-title":"Design, synthesis and antitumor activity of a novel class of SHP2 allosteric inhibitors with a furanyl amide-based scaffold","volume":"67","author":"Zhu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib37","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117687_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115585","article-title":"Design, synthesis, activity and molecular dynamics studies of 1,3,4-thiadiazole derivatives as selective allosteric inhibitors of SHP2 for the treatment of cancer","volume":"258","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117687_bib39","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2025.117687_bib40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expet Opin. Drug Discov."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T08:16:10Z","timestamp":1748420170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425004520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"alternative-id":["S0223523425004520"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117687","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, anticancer activity evaluation and molecular dynamics study of pyrazine N-oxide-based SHP2 allosteric inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117687"}}